Cipla gets EIR from USFDA for facility at Goa

05 Apr 2019 Evaluate

Cipla has received Establishment Inspection Report (EIR) from US Food & Drug Administration (USFDA) for Goa manufacturing facility. The inspection was carried out by USFDA from January 26, 2019 to January 28, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1498.50 -1.50 (-0.10%)
17-Dec-2025 09:27 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.45
Dr. Reddys Lab 1273.40
Cipla 1498.50
Zydus Lifesciences 920.00
Lupin 2118.85
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×